Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.

about

Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.

Item

http://www.wikidata.org/entity/Q54978314

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Combination of two anti-tubuli ...... nchymal-epithelial transition.

@en

Combination of two anti-tubuli ...... nchymal-epithelial transition.

@nl

type

Item

label

Combination of two anti-tubuli ...... nchymal-epithelial transition.

@en

Combination of two anti-tubuli ...... nchymal-epithelial transition.

@nl

prefLabel

Combination of two anti-tubuli ...... nchymal-epithelial transition.

@en

Combination of two anti-tubuli ...... nchymal-epithelial transition.

@nl

P1476

Combination of two anti-tubuli ...... nchymal-epithelial transition.

@en

P2093

Ken-Ichi Ito

http://www.w3.org/2001/XMLSchema#string

Takaaki Oba

http://www.w3.org/2001/XMLSchema#string

P2860

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis

Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells

Triple-Negative Breast Cancer

Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies

P304

22986-23002

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25184

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29796167

http://www.w3.org/2001/XMLSchema#string

P932

5955406

http://www.w3.org/2001/XMLSchema#string